Kardiologiia · 2016
[Evaluation of Antihypertensive Efficacy and Patient Adherence to Treatment With the New Formulation Perindopril Arginine (Orally Disintegrating Tablet) in General Clinical Practice: OPTIMUM Program].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Glezer On Behalf Of The Optimum Program Participants M G
Аннотация
UNLABELLED: The purpose of this study was to evaluate the antihypertensive efficacy of perindopril arginine in the oral dispersible form of tablets, in clinical practice.
MATERIALS AND METHODS: Post-marketing observational open program OPTIMUM was carried out from october 2014 to march 2015 year in 48 cities of the Russian Federation, 197 doctors. The observation included 957 patients. Prematurely retired from the study 17patients completed the observation in accordance with the protocol of 940 people.
RESULTS: Of the patients included men was 40.8%, 28.1% smokers , obese patients were 32.2% , cholesterol >5.0 mmol/l - 54.1%, diabetes - 13.3% . Angina was at 19.5% of patients had previous myocardial infarction, 5.3%, 3.7% of stroke, heart failure, was at 26.5% . Previously treated with 16% of patients , 53% had received monotherapy 2-koponentnuyu - 35% 3-component therapy and more 13% of patients. Angiotensin converting enzyme obtained 50.9% of the patients, 20.2% Sartana, diuretics - 22.9%, -blockers - 25.8%, calcium antagonists - 13.6% other drugs - 2.2%. With the inclusion in the program every fifth patient had BP Stage I level and included patients had hypertension II degree. The mean duration of disease was 7.0+/-6.2 years (median 5 years). When replacing the previously used ACE inhibitors or sartans on mouth-dispersible form of perindopril arginine BP decreased from 140,9+/-12.7/84.2+/-7.6 to 127.0+/-8.4/78.1+/-5.8 mm Hg. Target BP <140/90 mm Hg 91.4% of patients reached after 3 months of treatment. Adherence to the treatment of patients improved significantly and the total score increased from an average of 2.76+/-1.25 to 3.57+/-0.89 points (p<0.00001). When filling out a special questionnaire >2/3 of patients agreed or strongly agreed with the statements that orodispersible form is more easy to use, dissolves quickly and easily swallowed, is more convenient for the reception is at home or traveling.
CONCLUSION: It can be expected that the extension of the possibility of using perindopril arginine, including through the appointment of a new form for the reception, can lead to increased adherence to treatment, improve blood pressure control and reduce the incidence of adverse events in patients with hypertension.
MATERIALS AND METHODS: Post-marketing observational open program OPTIMUM was carried out from october 2014 to march 2015 year in 48 cities of the Russian Federation, 197 doctors. The observation included 957 patients. Prematurely retired from the study 17patients completed the observation in accordance with the protocol of 940 people.
RESULTS: Of the patients included men was 40.8%, 28.1% smokers , obese patients were 32.2% , cholesterol >5.0 mmol/l - 54.1%, diabetes - 13.3% . Angina was at 19.5% of patients had previous myocardial infarction, 5.3%, 3.7% of stroke, heart failure, was at 26.5% . Previously treated with 16% of patients , 53% had received monotherapy 2-koponentnuyu - 35% 3-component therapy and more 13% of patients. Angiotensin converting enzyme obtained 50.9% of the patients, 20.2% Sartana, diuretics - 22.9%, -blockers - 25.8%, calcium antagonists - 13.6% other drugs - 2.2%. With the inclusion in the program every fifth patient had BP Stage I level and included patients had hypertension II degree. The mean duration of disease was 7.0+/-6.2 years (median 5 years). When replacing the previously used ACE inhibitors or sartans on mouth-dispersible form of perindopril arginine BP decreased from 140,9+/-12.7/84.2+/-7.6 to 127.0+/-8.4/78.1+/-5.8 mm Hg. Target BP <140/90 mm Hg 91.4% of patients reached after 3 months of treatment. Adherence to the treatment of patients improved significantly and the total score increased from an average of 2.76+/-1.25 to 3.57+/-0.89 points (p<0.00001). When filling out a special questionnaire >2/3 of patients agreed or strongly agreed with the statements that orodispersible form is more easy to use, dissolves quickly and easily swallowed, is more convenient for the reception is at home or traveling.
CONCLUSION: It can be expected that the extension of the possibility of using perindopril arginine, including through the appointment of a new form for the reception, can lead to increased adherence to treatment, improve blood pressure control and reduce the incidence of adverse events in patients with hypertension.